Resolution criteria on PolyGram: As of market creation, Charles River Laboratories is estimated to release earnings on May 7, 2026. The Street consensus estimate for Charles River Laboratories’s non-GAAP EPS for the relevant quarter is $1.94 as of market creation. This market will resolve to "Yes" if Charles River Laboratories reports non-GAAP EPS greater than $1.94 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Charles River Laboratories releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha.
PolyGram is an on-chain prediction market where you trade YES or NO outcome shares with real USDC on Polygon. For this market, buy YES if you believe the event will happen, or NO if you think it won't. Your maximum loss is your stake — winning shares pay $1.00 each at resolution. Unlike sportsbooks, there is no house edge: prices are set by supply and demand from other traders and reflect the crowd's real-time probability.
Market outcomes
| Will Charles River Laboratories (CRL) beat quarterly earnings? | 100% YES | 0% NO |
Charles River Laboratories will report first-quarter 2026 earnings on 7 May, with the Street consensus targeting non-GAAP EPS of $1.94. The market currently reflects 100% implied probability of a beat, suggesting the order book has priced in minimal downside risk to consensus estimates. This extreme confidence warrants scrutiny against historical earnings patterns and the company's recent operational trajectory.
CRL has demonstrated consistent earnings delivery over recent quarters, though the contract research organisation sector faces cyclical pressures tied to pharmaceutical client spending and clinical trial activity. The 100% probability reflects either exceptionally strong forward guidance from the company, analyst confidence in management execution, or thin order book liquidity at the extremes. Historical precedent shows that CRL occasionally misses consensus on specific metrics whilst beating on others, and consensus estimates themselves can shift materially in the weeks preceding earnings release.
Traders should monitor any pre-earnings announcements regarding client wins, contract delays, or workforce adjustments through early May. Broader biotech sector momentum and any commentary from peer companies on clinical trial pipelines could influence near-term expectations. The settlement window closes at 13:00 UTC on 7 May, likely shortly after market open in New York, meaning the actual earnings release timing and non-GAAP EPS figure will determine resolution with minimal trading window thereafter.
The Charles River, sometimes called the River Charles or simply the Charles, is an 80-mile-long (129 km) river in eastern Massachusetts. It flows northeast from Hopkinton to Boston along a meandering route which doubles back on itself several times and travels through 23 cities and towns before reaching the Atlantic Ocean.
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span a
Charles River Bridge v. Warren Bridge, 36 U.S. 420 (1837), was a case regarding the Charles River Bridge and the Warren Bridge of Boston, Massachusetts, heard by the United States Supreme Court under the leadership of Chief Justice Roger B. Taney.
Charles River Reservation is a 17-mile-long (27 km) urban preserve and public recreation area located along the banks of the Charles River in Boston, Cambridge, Watertown, and Newton, Massachusetts. The reservation is managed by the Massachusetts Department of Conservation and Recreation. The portion of the reservation between the Charles River Dam and the E
This market settles from the official outcome published at https://seekingalpha.com/. A proposer submits the final result to the UMA optimistic oracle on Polygon; the two-hour dispute window closes and payouts clear in USDC.
The mechanics for trading "Will Charles River Laboratories (CRL) beat quarterly earnings?" are the same as any other PolyGram event contract. Each YES share resolves to $1 if the event happens, or $0 if it doesn't. The current price between 0¢ and 100¢ is the market's probability estimate, set live by the order book.
$2K in lifetime turnover and $0 of resting liquidity puts this market in the below the median by volume for finance contracts on PolyGram. Order-book depth is thin — large orders may need to be split across the book or executed as limit orders.
The market has been open for under a month — fresh enough that information asymmetry remains a real factor.
Higher-volume markets tend to have tighter spreads and faster price discovery — meaning the displayed YES/NO percentages are more likely to reflect the true crowd-implied probability rather than a single trader's directional view.
As of today, traders on Polymarket price this outcome at 100%. The number updates continuously as the order book clears. PolyGram mirrors the same live odds with locale-aware formatting and USDC settlement.
Resolution is sourced from https://seekingalpha.com/. Settlement is executed by the UMA optimistic oracle on Polygon, with a 2-hour dispute window before payouts clear.
This prediction market is scheduled to close on 7 May 2026. After the resolving event occurs, settlement typically clears within 24 hours once the UMA optimistic oracle confirms the outcome. All payouts are in USDC on the Polygon network.
To trade on this prediction market, create a free PolyGram account at polygram.ink, deposit USDC via Polygon, and place a YES or NO order on the outcome you believe in. You can learn more on our how-it-works page. Your maximum loss is limited to your stake — there is no leverage or margin.
When the outcome is determined, winning YES shares pay out $1.00 each in USDC, while losing shares pay $0. Settlement is handled by the UMA optimistic oracle on Polygon — a proposer submits the result, a two-hour dispute window opens, and if uncontested, payouts are distributed automatically. You can withdraw your winnings to any Polygon wallet.
Prediction-market positions can lose 100% of staked capital. Outcomes are uncertain by definition — historical accuracy of crowd-implied probabilities is high in aggregate but not for any single market. PolyGram does not provide investment advice. Trade only with capital you can afford to lose.
Regulatory status varies by jurisdiction. Germany, the United States, and most EU countries treat Polymarket-style event contracts under one of three frameworks: financial derivative, gambling product, or unregulated novel asset. Consult local counsel before trading.
Explore more prediction market odds and trading opportunities on PolyGram: